Sector News

Roche buys German genomics group Signature

February 10, 2015
Life sciences
Roche has hit the acquisition trail again to buy privately-held Signature Diagnostics of Germany.
 
The Potsdam-based firm is a translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers, including colorectal and lung. Signature uses the samples from its biobanks along with accompanying clinical progression and genetic data to develop and validate circulating cell free DNA (cfDNA) tests.
 
Roche says these tests have the potential to advance non-invasive treatment response monitoring for patients with cancer. Roland Diggelmann, head of its diagnostics unit, stated that biobanks play an important role in aiding translational research and the development of personalised therapies for patients.
 
He added that Signature “represents a unique bridge between high value cancer biobanks and next generation sequencing (NGS) assay development”. The German group will be integrated into Roche Sequencing Unit, which has grown through the recent acquisitions of Bina Technologies and Genia Technologies.
 
Financial terms have not been disclosed.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.